RxDoctor Payments Data

Smitha Kumar, MD

Family Medicine · Gilroy, CANPI 1619965688

Payments from drug & device makers

$1,915in general payments, 2019–2025

Across 121 payments — averaging $15.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$294
  • Johnson & Johnson$244
  • Amgen$171
  • Novo Nordisk$152
  • Boehringer Ingelheim$147
  • AstraZeneca$115
  • plus $792 from 14 others

What the payments were for

  • Food & beverage$1,80494%
  • Education$1126%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,915 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$302,925
Medicare patients
494
Services billed
2,749

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide136$164,721
JardianceEmpagliflozin113$142,220
FarxigaDapagliflozin Propanediol94$102,799
TrulicityDulaglutide68$75,422
MounjaroTirzepatide47$60,580
TradjentaLinagliptin67$56,645
MyrbetriqMirabegron60$49,639
EliquisApixaban47$42,496
Trelegy ElliptaFluticasone/Umeclidin/Vilanter53$34,602
XareltoRivaroxaban25$30,927
CreonLipase/Protease/Amylase11$15,364
Breo ElliptaFluticasone/Vilanterol18$9,654
Atrovent HfaIpratropium Bromide14$6,498
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog19$6,473
SymbicortBudesonide/Formoterol Fumarate16$5,682

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$147$198,866180 claims
Novo NordiskOzempic$152$164,721136 claims
Lilly USA, LLCTrulicity, Mounjaro$89$136,002115 claims
AstraZenecaFarxiga, Symbicort$115$108,481110 claims
Astellas Pharma US IncMyrbetriq$100$49,63960 claims
PfizerEliquis, Premarin$99$44,72461 claims
GSKTrelegy Ellipta, Breo Ellipta$294$44,25671 claims
Johnson & JohnsonXarelto$244$30,92725 claims
AbbVieCreon, Synthroid$29$16,96940 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,533 family medicine providers in California.

Other family medicine in Gilroy

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →